This article is more than 5 years old. Information may no longer be current.

Tear Film Innovations completes Series B funding

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tear Film Innovations has completed $8.5 million in Series B funding, the company announced in a press release.

Led by Visionary Ventures Fund and Bluestem Capital, the funding will be used as growth capital for the iLux evaporative dry eye system, which received 510(k) clearance from the FDA in December 2017 and provides targeted therapy to blocked meibomian glands through an in-office treatment.

“The early, enthusiastic response to the iLux system from both the ophthalmic and optometric sectors is very encouraging,” OSN Chief Medical Editor Richard L. Lindstrom, MD, a member of the Visionary Ventures Fund investment team, said in the release. “Dry eye continues to dominate the clinical and commercial landscape in eye care, and we are confident the iLux device will play a significant role moving forward.”